Thursday, January 7, 2016

Alector Raises $29.5M For Alzheimer's Treatments

San Francisco-based Alector, a developer of immuno-modulatory therapies for Alzheimer's disease and other neurodegenerative disorders, announced today that it has raised $29.5M in a Series D financing. The funding was led by Dementia Discovery Fund, and also included Amgen Ventures and AbbVie, plus prior investors Merck Research Lab Ventures, OrbiMed, Polaris Partners, GV (formerly Google Ventures), Topspin Partners and Mission Bay Capital. Alector is led by Arnon Rosenthal. More information »